Wall Street Zen Upgrades Xilio Therapeutics (NASDAQ:XLO) to Buy

Xilio Therapeutics (NASDAQ:XLO) was upgraded by Wall Street Zen from a “hold” rating to a “buy” rating in a note issued to investors on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xilio Therapeutics in a research note on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Xilio Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $28.00.

Xilio Therapeutics Price Performance

Shares of XLO stock opened at $8.32 on Friday. The firm has a market capitalization of $48.09 million, a price-to-earnings ratio of -1.51 and a beta of -0.05. The stock has a fifty day moving average of $7.96 and a 200 day moving average of $9.56. Xilio Therapeutics has a 52 week low of $6.47 and a 52 week high of $16.52.

Xilio Therapeutics (NASDAQ:XLO) last issued its quarterly earnings data on Monday, March 23rd. The company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.68) by $0.83. Xilio Therapeutics had a negative net margin of 80.05% and a negative return on equity of 393.01%. The business had revenue of $13.69 million for the quarter, compared to the consensus estimate of $10.90 million. Equities research analysts anticipate that Xilio Therapeutics will post -1.14 earnings per share for the current year.

Institutional Trading of Xilio Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Squarepoint Ops LLC boosted its stake in Xilio Therapeutics by 39.6% during the third quarter. Squarepoint Ops LLC now owns 328,794 shares of the company’s stock worth $277,000 after acquiring an additional 93,338 shares in the last quarter. Empery Asset Management LP bought a new position in shares of Xilio Therapeutics during the fourth quarter valued at approximately $757,000. Renaissance Technologies LLC increased its stake in shares of Xilio Therapeutics by 68.3% during the fourth quarter. Renaissance Technologies LLC now owns 344,416 shares of the company’s stock valued at $220,000 after purchasing an additional 139,716 shares in the last quarter. Jane Street Group LLC bought a new position in shares of Xilio Therapeutics during the fourth quarter valued at approximately $27,000. Finally, State Street Corp lifted its holdings in shares of Xilio Therapeutics by 13.7% during the fourth quarter. State Street Corp now owns 186,390 shares of the company’s stock valued at $119,000 after purchasing an additional 22,500 shares during the last quarter. 54.29% of the stock is owned by hedge funds and other institutional investors.

Xilio Therapeutics Company Profile

Xilio Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of tumor‐targeted cytokine therapeutics for the treatment of cancer. The company leverages a proprietary platform to design pro‐drug versions of potent immune‐modulating cytokines, enabling local activation of immune responses within the tumor microenvironment while limiting systemic exposure and toxicity.

The company’s lead programs utilize engineered interleukin‐12 (IL‐12) and interleukin‐2 (IL‐2) molecules fused to tumor‐binding antibodies or peptide ligands.